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Abstract
Background: Transcriptome analysis by microarrays has produced important advances in biomedicine. For instance
in multiple myeloma (MM), microarray approaches led to the development of an effective disease subtyping via
cluster assignment, and a 70 gene risk score. Both enabled an improved molecular understanding of MM, and have
provided prognostic information for the purposes of clinical management. Many researchers are now transitioning
to Next Generation Sequencing (NGS) approaches and RNA-seq in particular, due to its discovery-based nature,
improved sensitivity, and dynamic range. Additionally, RNA-seq allows for the analysis of gene isoforms, splice
variants, and novel gene fusions. Given the voluminous amounts of historical microarray data, there is now a need
to associate and integrate microarray and RNA-seq data via advanced bioinformatic approaches.
Methods: Custom software was developed following a model-view-controller (MVC) approach to integrate
Affymetrix probe set-IDs, and gene annotation information from a variety of sources. The tool/approach employs
an assortment of strategies to integrate, cross reference, and associate microarray and RNA-seq datasets.
Results: Output from a variety of transcriptome reconstruction and quantitation tools (e.g., Cufflinks) can be
directly integrated, and/or associated with Affymetrix probe set data, as well as necessary gene identifiers and/or
symbols from a diversity of sources. Strategies are employed to maximize the annotation and cross referencing
process. Custom gene sets (e.g., MM 70 risk score (GEP-70)) can be specified, and the tool can be directly
assimilated into an RNA-seq pipeline.
Conclusion: A novel bioinformatic approach to aid in the facilitation of both annotation and association of historic
microarray data, in conjunction with richer RNA-seq data, is now assisting with the study of MM cancer biology.
Background
Cancer diagnostics are now being revolutionized by
advances and insights from biotechnology, computational
science, and molecular biology. Molecular profiling
approaches to both discover and better define individual
patterns of disease related molecules is a principle require-
ment of precision medicine [1]. By revealing the molecular
taxonomy of a patient’s tumor, a precise and rational
approach to treatment may be applied. This allows for
customized therapeutic regimens versus categorical
assignments. Improved therapeutic efficacies along with
the minimization of toxicity are the principle aims [2,3].
Multiple Myeloma (MM) is a cancer of the bone
marrow and is characterized by a malignant proliferation
of plasma cells. Clinically, MM is typified by osteolytic
bone lesions, anemia, hypercalcemia, and renal failure
[4,5]. There are approximately 20,000 new cases and
10,000 deaths estimated to occur in the United States each
year [6]. MM is generally considered incurable, with a
clinical course characterized by remissions and relapses
[7]. Patient survival has improved dramatically in the past
10-15 years, due to scientific and technological advances,
which have enabled an improved understanding of the
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cancer biology. This has led to two new classes of medica-
tions, (Immunomodulatory drugs (IMiDs), e.g., thalido-
mide, lenalidomide, pomalidomide; and proteasome
inhibitors, e.g., bortezomib, carfilzomib), new therapeutic
approaches (e.g., autologous tandem transplant), and
advances in cancer-based supportive care (e.g., bispho-
sphonates for bone metastasis) [8-10].
Microarray-based transcriptome approaches have
resulted in: i) disease subtyping for MM, ii) the establish-
ment of a 70 gene prognostic risk score (GEP-70) and, iii)
the identification of therapeutic drug targets (e.g., DKK1)
[11-14]. An improved understanding of MM on a molecu-
lar level has been achieved by these three accomplish-
ments. Additionally, they have provided much needed
prognostic information. Such information serves to assist
with clinical management in settings of initial diagnosis,
relapse, and also therapeutic assignments.
A commercial transcriptome-based molecular profiling
assay for multiple myeloma does now exist. It is marketed
by Signal Genetics (http://www.myelomahealth.com). The
assay is called “MyPRS Plus” and is based on microarray
technology. Certainly, if this assay is used in a phase III
clinical trial, prognostication abilities may be appropriately
evaluated.
By far the most mature use of advanced clinical assays,
and molecular profiling in particular, is in breast cancer.
Transcriptome-based molecular methods have resulted in
two key assays, MammaPrint and Oncotype DX®, which
are now contained in the National Comprehensive Cancer
Network® (NCCN®) guidelines [15,16]. MammaPrint is a
70 gene assay and has been approved by the FDA to assist
with the assessment of recurrence of disease for women
younger than 61 with certain types of breast cancer. Onco-
type DX is a 21 gene assay for hormone receptor positive,
axillary lymph node negative breast cancer, and quantifies
the risk of recurrence as a continuous variable. The
clinical question being addressed by OncoType DX is, if
chemotherapy is given, will it be beneficial. Both assays are
used in the prognostication of certain breast cancers
[17,18]. The use of gene-expression signatures empowers
the identification of specific subclasses of breast cancer.
For over seven years, both assays have been used, and
have displayed significant clinical utility [19]. Finally,
clinical trials have been utilized to critically assess the
effectiveness of these assays. [20-23]
Many researchers are now transitioning to Next Genera-
tion Sequencing (NGS) approaches and RNA-seq in parti-
cular, due to its discovery-based nature, improved
sensitivity, and dynamic range. Table 1 is adapted from
Wang, et. al.,[24] and showcases the major differences
between microarray and RNA-seq technologies. Compared
to microarray technologies, generally RNA-seq requires
less mRNA, has single base resolution, and is able to
distinguish allelic expression, splice isoforms, and discover
new genes. Strandedness can also be accommodated,
which improves specificity during data analysis. Compared
to microarray analysis the computational requirements for
RNA-seq are much more complex. The term “cost” refers
to financial cost, and reflects computational hardware
including infrastructure, as well as the time and expertise
for data analysis. The correlation between microarray and
RNA-seq data is problematic primarily due to dynamic
range differences [25].
The association and integration of historic microarray
and RNA-seq data is now an urgent need. This is espe-
cially true for cancer centers or institutes with a focus on a
particular disease. In these cases, an evolutionary shift in
technology may have a disruptive effect, on scientific
workflows and associated endeavors, as well as advanced
clinical care regimens. Thus, there is a need for disease-
based customization built into the advanced bioinformatic
methods, which can facilitate in the transition from an
older or historic technology (e.g., microarrays) to a new or
evolving approach (e.g., RNA-seq) [26,27].
In this study, custom software tools have been devel-
oped, some following a model-view-controller (MVC)
approach, in order to integrate Affymetric probe set-IDs,
and gene annotation information from a variety of sources.
Our approach employed a mixture of strategies to maxi-
mize the integration, annotation, and association of micro-
array and RNA-seq datasets. Importantly, our approach is
independent of any particular type of transcriptome recon-
struction or quantitation tool(s), or file format (e.g. GTF,
GFF). Input requirements simply consist of a tab delimited
file with column one being an Ensembl Gene ID (if
known) and column two being the gene symbol.
Additional columns are imported and associated in a
record/set-based manner.
For illustrative purposes, output from Cufflinks [28], is
directly integrated into a tool pipeline. However,
Table 1 Microarray vs. RNA-seq
Microarray RNA-seq
Principle Hybridization Cloning & sequencing
Required amount of RNA High Low






Distinguish splice forms? Limited Yes
Discover new genes? No Yes
Strandedness? No Yes




Cost Medium High (due to
computation)
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following our tool and file independent design approach,
other reconstruction tools such as IsoLasso[29] or TRIP
[30], and/or other quantification tools IsoEM[31] or
RSEM[32] may be utilized. Finally, multiple myeloma
and its associated cancer biology knowledge is utilized
and structured to further illustrate the disease-based
cross reference operations and annotation strategies, for
more effective data culling and exploration. Eventually,
we would like to make our software available to the
greater scientific community, possibly as open source.
Methods
I. Data sets used in this study and database generation
The following files and conversion/association-type
annotations were utilized in order to perform proper
cross referencing from Affymetrix probe set-IDs to
Ensembl gene IDs.
1. Affymetrix annotation for gene cross references (HG-
U133_Plus_2 Annotations, CSV format, Release 33 (last
update 10/30/12)) was obtained from the Affymetrix
website (http://www.affymetrix.com).
2. The Ensembl gene cross references to Affymetrix
probe set annotation was obtained using the query
interface of Ensembl BioMart (http://www.ensembl.org/
biomart/martview/). Key parameters utilized were: Dataset
- Homo sapiens genes - GRCh37.p10/ Ensembl Genes
71 and Attributes - Affy HG U133 Plus 2 probe set).
Additionally, the Ensembl GTF file (ftp://ftp.ensembl.org/
pub/release-71/gtf/homo_sapiens) was also obtained. This
file contains Ensembl gene based annotations for corre-
sponding transcripts, as well as chromosomal locations.
3. NCBI gene annotations were obtained from ftp://
ftp.ncbi.nlm.nih.gov/gene/DATA/gene2accession.gz,
ftp://ftp.ncbi.nlm.nih.gov/gene/DATA/gene_info.gz via
the NCBI ftp site, (ftp://ftp.ncbi.nlm.nih.gov/gene/
DATA/)
All files were parsed to create a series of look up tables.
Subsequently association relationships were further
defined and a schema design established. A relational
database was created using Microsoft SQL Server 2012 to
implement the aforementioned design.
II. Association algorithms
Associations between Affymetrix probe set-IDs and
Ensembl gene identifiers as well as gene symbols were
established by either an indirect or direct method. The
algorithmic approach is illustrated in Figure 1.
Algorithm for direct association
Direct association utilizes cross references available from
within the Affymetrix annotation file. This involves first
identifying the Affymetrix probe set-ID corresponding
to a given Ensembl Gene ID or gene symbol. This is
obtained by querying the association look up tables of
Ensembl gene to Affymetrix probe set-ID or gene
Figure 1 Affymetrix to NGS association tool algorithm. Associations between Affymetrix probe setIDs and Ensembl gene identifiers as well as
gene symbols are established by either a direct or indirect method.
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symbol to Affymetrix probe set-ID relationships. For
example, given the Ensembl gene ID, “ENSG00009879”,
a corresponding Affymetrix probe set-ID was searched
and identified using a specific SQL query.
Algorithm for indirect association
Indirect association involves the use of additional exter-
nal data sources and a variety of strategies are utilized.
We established cross references from NCBI and
Ensembl BioMart to enhance our association abilities.
This method is automatically invoked when the direct
association approach is not successful. The indirect
method may first involve using a Genebank Accession
and associating to an Entrez Gene ID, then associating
the Entrez Gene ID to both an Affy probe set-ID(s) and
if possible, also a Gene Symbol (for completeness).
Alternatively, a Genebank Accession may be associated
to an Ensembl Gene ID, then that Ensembl Gene ID is
associated to an Affy probe set-ID(s), and if possible a
Gene Symbol. Finally, a gene symbol may be associated
either to an Ensembl Gene ID or Entrez Gene ID
(depending on success) and then the Ensembl or Entrez
Gene ID associated to an Affy probe set-ID(s).
Algorithm for locus based association
In locus based association, given a chromosomal location,
a set of genes that associate to that specific location can be
obtained. This is achieved by querying for an association
locus in a table based on the Ensembl annotations. This
table contains a chromosomal location and structure for
each Ensembl Gene ID.
III. Interface
Supported are both browser-based and command line
interfaces. The web browser interface design follows a
model-view-controller (MVC) approach. Figure 2 illus-
trates the approach for our system. Here, the display
functionality of the interface is separated from the
model (database) elements, by using a set of controllers.
Using the aforementioned software engineering architec-
tural method promotes code reusability, modularity and
extensibility. Thus, future design enhancements, e.g.,
new features and functions, can be added in an efficient
manner.
Basic association using web or command line interface
The user interface is illustrated in Figure 3. The web inter-
face is dynamic and takes as input the output of Cufflinks,
or similar tool. Input formatting consists of an Ensembl
Gene ID in the first column, and a gene symbol or gene
accession number in the second column, respectively.
Additional columns/variables are able to be imported and
conveyed in a seamless manner to allow existing data to
be further annotated with association data. The aim is to
associate the Gene IDs or the GenBank accessions, and
Figure 2 Design of the NGS association system. A model-view-controller (MVC) software engineering architecture methodology was utilized
to promote code reusability, modularity, and extensibility.
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Gene symbols with the corresponding Affymetric probe
set-ID(s) using the association algorithms. Thus, the gene
ID or gene symbol is associated by a direct or indirect
method, with the purpose to cross reference an Affymetric
probe set-ID. Additional columns of data from Cufflinks
or similar tool are conveyed with the data set and incorpo-
rated into a relational framework. Finally, connecting the
same RNA-seq data with multiple microarray experiments
is performed simply by invoking an additional instance of
the software, specifying the desired data sets and display/
monitor.
A command line interface is also provided. In a standa-
lone manner, the association and cross referencing
capabilities are utilized. A single line command specifying
the input and output files is required.
Cell culture material
The following MM cell lines were used in this study.
RPMI 8226 was obtained from ATCC (Cat # CCL-155).
H929 was also obtained from ATCC (Cat # CRL-9068).
All cell lines were grown in RPMI-1640 medium
(ATCC, Cat # 30-2001) with 10% FBS. RNA was
extracted using the RNeasy kit (Qiagen) according to
manufacturer instructions.
Microarray and RNA-seq datasets
All microarray data files were obtained from the study
archive section in our MM historical database. See
Figure 4, GEP Historical DB. Microarray datasets were
processed as previously reported [33].
For each RNA-seq sample, we prepared Illumina
mRNA-seq libraries using the TrueSeq mRNA kit v2. The
starting sample material was 100 ng of total RNA and
fashioned according to the manufactures instructions.
Poly-A selection for mRNA isolation using streptavidin-
coated magnetic beads, followed by thermal mRNA
fragmentation, was used during the sample prep process.
The fragmented mRNA was subjected to cDNA synthesis
using reverse transcriptase according to the manufac-
turer’s instructions. The cDNA was then converted into
double stranded cDNA followed by an end repair process,
and then ligated to Illumina paired end (PE) adaptors. Size
selection was performed using AMPure XP beads (Beck-
man Coulter), generating cDNA libraries ranging in size
from 300 to 350 bp (base pairs). Libraries were then
enriched using 15 cycles of PCR and purified again by
AMPure XP beads. Each library was run at a concentra-
tion of 10 pM. All RNA-seq experiments were run on an
Figure 3 Interface for the NGS association system. Both web browser and command line interfaces are supported. The web interface is
dynamic and takes as input the output of Cufflinks or similar tool. The NGS association system is independent of any particular transcriptome
reconstruction or quantitation tool or file format. Input formatting solely consists of an Ensembl Gene ID in the first column, and gene symbol or
gene accession number in the second column, respectively. Additional columns/variables are able to be imported and conveyed in a seamless
manner. Using association algorithms, the aim is to link Gene IDs or GeneBank accessions, and Gene symbols with corresponding Affy probe set-
ID(s).
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Illumina HiSeq-2000 in an identical manner utilizing 101
bp PE sequencing. In summary, the fragment length is
~300-350 bp and thus the inner-mate-distance is ~98-148
bp since we are performing 101 bp PE sequencing.
RNA-seq read alignment and transcriptome processing
The RNA-seq data analysis utilized the Tuxedo suite. All
files/experiments were processed in an identical manner
using a standard pipeline protocol. RNA-seq reads for
each library were mapped independently using TopHat
version 2.0.8 (http://tophat.cbcb.umd.edu/) against the
human genome build hg19. HiSeq 2000 libraries were
aligned with the following options: “-p 8 -G Ensembl.gtf”,
where Ensembl.gtf contains the coding transcripts in GTF
format. Basic statistics of the two RNA-seq data sets used
in this study can be found in additional file 1. Cufflinks
version 2.1.1 (http://cufflinks.cbcb.umd.edu/) was run
separately for transcriptome reconstruction and quantita-
tion for each generated BAM file with the following
options: “-p 8 -g Ensembl.gtf”, thus allowing for both
annotation and novel transcript discovery.
Results and discussion
In this study, custom software methodologies have been
developed to integrate and cross reference Affymetrix
probe set-IDs and gene annotation information from a
variety of sources. Given our current and historical work
involving microarray technology and disease focus at
MIRT (Myeloma Institute for Research and Therapy), a
review of key microarray experiments and the cancer
biology gleaned was cataloged and studied. Further
analyses and computational exercises were then
conducted. Methods to best incorporate particular types
of cancer biology knowledge gained from microarray
studies for leveraging purposes towards RNA-seq, as well
as strategies for association, data reduction, display and
biological correlation were pursued and continue to be an
active research area.
The web interface enables one to associate from
Ensembl Gene IDs to Affymetrix probe set-IDs in simple
steps. The user can upload as input, a Cufflinks (or similar
tool) file, using the ‘Browse’ button. By clicking the ‘Pro-
cess’ button, RNA-seq gene IDs are associated internally.
The result is an Affymetrix annotated Cufflinks data file,
which is displayed in a panel, as well made available in the
form of a downloadable file. Such steps are illustrated in
the figure contained in additional file 2. The ‘Filter by
member list’ option is used to reduce a RNA-seq dataset
to a smaller list of biologically relevant members, e.g. the
70 probe sets that make up the GEP-70 risk score [11].
This is displayed in additional file 3. Finally, a biologically
deeper view of the experimental data is obtained by
expanding the gene list to include the corresponding
isoform transcripts using the ‘isoform tree’ option. This is
shown in additional file 4. Here an isoform level analysis
of the output from the differential expression aspect of
Cufflinks (i.e., Cuffdiff) is displayed by our tool for the
genes YWHAZ, CCT2 (note: compressed isoform tree),
andWEE1.
In addition to association, one can also use or create
custom gene lists. Figure 4 illustrates these concepts and
features implemented to date. A biologically directed
filtering through large RNA-seq datasets is the aim. We
Figure 4 Interface options for the NGS association system. A biologically directed filtering through large RNA-seq data sets allows the
researcher to quickly leverage and focus on important MM gene and gene isoform subsets, many of which were developed through microarray
approaches.
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have pre-built gene sets for known MM prognostic scoring
schemes, namely GEP-70, GEP-80 [33], as well as gene
sets for MM molecular subtypes [12]. Thus, researchers
can upload their RNA-seq Cufflinks file and then filter
their data by any of these criteria. For instance, a GEP-70
selection would result in a filtered list of 70 genes and
their corresponding expression values for the RNA-seq
genes and isoforms found in the sample input file. Hence,
the cancer biologist or clinical researcher can now quickly
leverage, target and focus on this important MM subset,
which was discovered and developed through microarray
approaches.
One of the advantages of RNA-Seq studies versus
microarray for transcriptome profiling is its single-base
level resolution. This allows expression detection at both a
gene and isoform level as opposed to only the gene level
for microarrays. Table 2 lists filtered experimental output
from a custom gene list composed of eight key MM genes.
The cell line H929, which was derived from a 62 year old
female with MM, was used in this experiment.
Here, the custom MM gene list is composed of:
CCND1, CCND3, DKK1, FGFR3, MAF, MAFB, NFKB1,
and WHSC1. The columns “Gene ID” and “Transcript
ID” contain the Ensembl designations. Note: if an iso-
form transcript is novel it will have a “CUFF” prefix.
The next two columns contain the respective Fragments
Per Kilobase of transcript per Million mapped reads
(FPKM) values. The remainder of the table contains a
representative Affymetrix probe set-ID, chromosome
number and location, and finally the Affy expression
value from the associated microarray experiment.
Applying visualization approaches to complex data may
aid in speeding analysis, as well as identifying key or subtle
trends and patterns. Thus, a continued research effort in
our group is to identify data sets amenable to an intuitive
graphic representation. Figure 5 is a system generated
graphic illustration of table 2. Section A shows the gene
expression values for both the microarray and correspond-
ing RNA-seq experiments. For RNA-seq data, Log2
(Expression) corresponds to Log2(FPKM). For microarray
data, Log2(Expression) corresponds to the log2 function
applied to the normalized absolute intensities from the
microarray. Bar plots are used as a visualization aid for the
tabular data, and are not meant as a direct comparison
between the two different platform technologies. The log2
approach is based on the publications from Mortazavi et
al., and Marioni et al.[25,34]Section B shows an isoform-
based composition, on a gene-by-gene basis, for the
RNA-seq gene expression values. The isoform graphic
allows for an easier identification of dominant forms.
Novel isoforms are denoted by an asterisk. Even simple
programmatic renderings of data, when structured with a
proper context, e.g., biological relevance, may aid with
analysis in a significant manner.
To further investigate the biological significance of
RNA-seq data, an interface to automatically invoke the
Integrative Genomics Viewer (IGV)[35] from the browser
with experimentally rendered data has been developed.
Table 2 Filtered experimental data from cell line H929
Gene
Name










CCND1 ENSG00000110092 ENST00000539241 19.5901 42.7301 208712_at chr11q13.2 279.6
CCND1 ENSG00000110092 CUFF.2094.1 15.7855 42.7301 208712_at chr11q13.2 279.6
CCND1 ENSG00000110092 ENST00000227507 7.35445 42.7301 208712_at chr11q13.2 279.6
CCND3 ENSG00000112576 ENST00000372991 43.8105 43.8105 1562028_at chr6p21.1 228.4
DKK1 ENSG00000107984 ENST00000373970 0.765215 1.24334 204602_at chr10q21.1 521.7
DKK1 ENSG00000107984 CUFF.403.1 0.478122 1.24334 204602_at chr10q21.1 521.7
FGFR3 ENSG00000068078 ENST00000260795 25.4733 48.3278 204380_s_at chr4p16.3 870.7
FGFR3 ENSG00000068078 CUFF.20476.3 12.4934 48.3278 204380_s_at chr4p16.3 870.7
FGFR3 ENSG00000068078 CUFF.20476.2 10.3612 48.3278 204380_s_at chr4p16.3 870.7
MAF ENSG00000178573 ENST00000393350 11.1179 23.4381 1566323_at chr16q23.1 7.1
MAF ENSG00000178573 CUFF.7714.4 7.70292 23.4381 1566323_at chr16q23.1 7.1
MAF ENSG00000178573 ENST00000326043 4.61729 23.4381 1566323_at chr16q23.1 7.1
MAFB ENSG00000204103 ENST00000373313 0.713849 0.713849 218559_s_at chr20q12 141.9
NFKB1 ENSG00000109320 CUFF.21095.8 7.80674 10.7257 209239_at chr4q24 977.1
NFKB1 ENSG00000109320 CUFF.21095.12 2.919 10.7257 209239_at chr4q24 977.1
WHSC1 ENSG00000109685 ENST00000508355 121.89 249.395 1557780_at chr4p16.3 643.5
WHSC1 ENSG00000109685 CUFF.20684.17 68.9562 249.395 1557780_at chr4p16.3 643.5
WHSC1 ENSG00000109685 ENST00000382891 58.5494 249.395 1557780_at chr4p16.3 643.5
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Additional file 5 illustrates this feature. Here, the
isoforms for FGFR3 are checked/selected for IGV view-
ing, analysis, etc. By programmatically generating the
necessary files required to view specific gene isoform
transcripts further analyses may be conducted. For
instance, novel and known/annotated isoform transcripts
can be graphically compared. Isoforms can also be inter-
rogated to the level of amino acid assignments according
to the three possible open reading frames (ORF) provided
by IGV. Thus, the relevance of isoforms can now be more
easily viewed, compared, and judged for biological
significance.
Additional file 6 contains results of an IGV analysis
from cell line H929, with gene DKK1, and concerns the
origin of the novel isoform CUFF.403.1. Note: Dickkopf-
related protein 1, which is encoded by the DKK1 gene,
is associated with osteolytic bone lesions in patients
with MM, and is also a known inhibitor of the WNT
signaling pathway. Because of this, DKK1 and its gene
products, are now the subject of active developmental
therapeutics drug targeting. Much of this early work
was accomplished with microarray technology at MIRT.
As shown in table 2 and Figure 5, only two DKK1 iso-
forms were found during the RNA-seq experiment.
These are ENST00000373970, which is known and
contained in the Ensembl annotation, and CUFF.403.1,
which is not known and is thus potentially novel. These
two detected isoforms are displayed in the pink region
of additional file 6, and the novel isoform (CUFF.403.1)
is colored green. In the IGV analysis, all four known
DKK1 isoform annotations from Ensembl are included
along with five red arrows, which serve to illustrate the
origin of the various coding segments comprising the
novel isoform CUFF.403.1. Thus in this case, the origin
of this discovered isoform appears to be the result of a
new alternative splicing of the mRNA for gene DKK1.
This potentially exciting finding was greatly aided by
prior MM microarray studies.
A second combined RNA-seq with microarray experi-
ment was performed utilizing the cell line RPMI 8226.
This cell line was derived from a 61 year old male
diagnosed with MM. The same eight key MM genes were
used and table 3 lists the filtered results. Only transcripts
from five of the eight genes were found in this particular
RNA-seq experiment. Figure 6 displays a computed
graphic representation of the gene expression values
(section A) for microarray and RNA-seq. A graphic illus-
tration of isoform contributions is contained in section B.
All computations and comparisons were performed in an
identical manner as in Figure 5. Although the Affymetrix
Figure 5 Visualizing gene and gene isoform expression data in the cell line H929. This is a system generated graphic illustration of table 2.
Section A shows the gene expression values for both the microarray and corresponding RNA-seq experiments. Here, for RNA-seq data, Log2
(Expression) corresponds to Log2(FPKM). For microarray data, Log2(Expression) corresponds to the log2 function applied to the normalized
absolute intensities from the microarray. Bar plots are used as a visualization aid for the tabular data, and are not meant as a direct comparison
between the two different platform technologies. Section B shows an isoform-based comparison, on a gene-by-gene basis, for the RNA-seq
gene expression values and allows for an easier identification of dominant forms.
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signal from FGFR3 is a bit low, it was chosen for illustra-
tive purposes.
Additional file 7 contains results of an automatically
invoked IGV analysis from cell line RPMI-8226, gene
FGFR3, and the three identified isoforms identified during
the RNA-seq experiment. Section A shows a graphic
comparison the two known/annotated Ensembl isoforms
(ENST00000340107 and ENST00000260795) along with
the discovered/novel isoform CUFF.23217.9. The unique
coding segment of CUFF.23217.9 is noted by the red
brace, and graphically its uniqueness is apparent. Thus,
step two of the analysis concerns biological relevance. An
interrogation of the amino acids that may be generated
from the unique coding segment of CUFF.23217.9 is
shown in section B. In each of the three ORFs, stop
codons are encountered.
If a novel isoform generates a stop codon early in the
corresponding amino acid chain, the protein viability is
highly unlikely. This is due to the nonsense-mediated
mRNA decay pathway. This may be contrary to intui-
tion, that the predominant consequence of nonsense
mutations is not the synthesis of truncated proteins.
Rather, these nonsense transcripts are recognized by the
cell and efficiently degraded [36]. Since stop codons are
occurring early in the protein sequence in all ORFs for
CUFF.23217.9, it is not biologically significant. Thus,
RNA-seq is serving to verify the impact of these non-
sense mutations.
Table 3 Filtered experimental data from cell line RPMI-8226
Gene
Name










CCND3 ENSG00000112576 ENST00000372991 137.068 137.068 1562028_at chr6p21.1 188.9
FGFR3 ENSG00000068078 CUFF.23217.9 1.27549 2.96453 204380_s_at chr4p16.3 202.9
FGFR3 ENSG00000068078 ENST00000340107 1.24395 2.96453 204380_s_at chr4p16.3 202.9
FGFR3 ENSG00000068078 ENST00000260795 0.445095 2.96453 204380_s_at chr4p16.3 202.9
MAF ENSG00000178573 ENST00000393350 0.00202724 0.00202724 1566323_at chr16q23.1 19.9
NFKB1 ENSG00000109320 ENST00000505458 17.3606 29.4494 209239_at chr4q24 1253.8
NFKB1 ENSG00000109320 ENST00000226574 12.0888 29.4494 209239_at chr4q24 1253.8
WHSC1 ENSG00000109685 ENST00000382891 38.771 55.1773 1557780_at chr4p16.3 32.2
Figure 6 Visualizing gene and gene isoform expression data in the cell line RPMI-8226. This is a system generated graphic illustration of
table 3. All computations and comparisons were performed in an identical manner as in figure 5.
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Conclusions
There is much to learn about the complexity of cancer
genomes. As technology advances, it will be critical to
continue to leverage what has been gained from historic
platform technologies (e.g., microarrays) to new
approaches (RNA-seq). Thus in addition to the requisite
bioinformatics-based migration due to technical aspects,
custom approaches, which harness particular salient
aspects of the biology of a disease, may be of assistance. In
this study, we have begun to lay a framework towards
such endeavors for MM. Specifically, through the creation
and development of novel bioinformatic approaches to aid
in the visualization and facilitation of both annotation and
association of historic microarray data in conjunction with
richer RNA-seq data. It is our hope that such efforts will
assist with our understanding of which genes are mutated,
the pathways impacted by these mutations, and how these
data inform our models of MM cancer biology, so as to
ultimately improve the outcomes of our patients.
Additional material
Additional file 1: Basic statistics for RNA-seq data sets.
Additional file 2: Initial loading and mapping of a Cufflinks data
file. The association of Ensembl Gene IDs to Affymetrix probe set-IDs can
be accomplished via simple steps by the web interface. A Cufflinks (or
similar tool) file may be uploaded as input via the “Browse” button. By
pressing the “Process” button, RNA-seq gene IDs are associated internally.
The Affymetrix annotated Cufflinks data file can then be display in a
panel and additionally be downloaded as a file.
Additional file 3: Filtering the Cufflinks data file by the GEP-70
gene list. The “Filter by member list” option is used to reduce a RNA-seq
dataset to a smaller list of biologically relevant members, in this case, the
70 probe sets that make up the GEP-70 risk score.
Additional file 4: Viewing Cufflinks (Cuffdiff) data at the isoform
level. A biologically deeper view of the experimental data is possible by
expanding the gene list to include corresponding isoform transcripts via
the “isoform tree” option.
Additional file 5: Interface for automatic invocation of IGV. An
interface to automatically invoke the Integrative Genomics Viewer (IGV)
from the NGS browser with experimentally rendered data was
developed. This facilitates further investigations regarding the biological
relevance of RNA-seq data streams.
Additional file 6: The origin of novel isoform CUFF.403.1 from gene
DKK1 and cell line H929. Two DKK1 isoforms were found during the
RNA-seq experiment and are contained in the pink region of the graphic
image. They are ENST00000373970, which is known and contained in the
Ensembl annotation, and CUFF.403.1, which is not known and is thus
potentially novel. The novel isoform is colored green. In IGV analysis, all
four known DKK1 isoform annotations from Ensembl are included along
with five red arrows, which serve to illustrate the origin of the various
coding regions comprising novel isoform CUFF.403.1. Here, the origin of
this discovered isoform appears to be the result of a new alternative
splicing of the mRNA for gene DKK1.
Additional file 7: Three identified isoforms for gene FGFR3 from cell
line RPMI-8226. An automatically invoked IGV analysis from cell line
RPMI-8226, gene FGFR3 reveals the three identified gene isoforms.
Section A displays the graphic comparison of the two known/annotated
Ensembl isoforms (ENST00000340107 and ENST00000260795) along with
the discovered/novel isoform CUFF.23217.9. The unique coding segment
of CUFF.23217.9 is noted by a red brace and labeled as a novel exon.
Section B contains the second step of the analysis, specifically, the
biological relevance of the novel exon. Here an interrogation of the
amino acids from each of the three open reading frames reveals stop
codons. As a result, the biological relevance of the novel exon is not
significant due to the likely activation of the nonsense-mediated mRNA
decay pathway, and thus no protein viability.
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